Complement-Mediated Synaptic Protection

Target: C1QA Composite Score: 0.580 Price: $0.62▲47.3% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.580

Top 50% of 1875 hypotheses

T3 Provisional

Single-source or model-inferred

Needs composite score ≥0.60 (current: 0.58) for Supported

B Mech. Plausibility 15% 0.60 Top 57%

C Evidence Strength 15% 0.40 Top 78%

B Novelty 12% 0.60 Top 66%

C+ Feasibility 12% 0.50 Top 65%

B+ Impact 12% 0.70 Top 51%

B Druggability 10% 0.60 Top 42%

D Safety Profile 8% 0.30 Top 92%

B Competition 6% 0.60 Top 56%

C+ Data Availability 5% 0.50 Top 71%

C+ Reproducibility 5% 0.50 Top 63%

Evidence

9 supporting | 3 opposing

Citation quality: 85%

Debates

1 session A+

Avg quality: 0.95

Convergence

0.57 C+ 7 related hypothesis share this target

From Analysis:

Neuroinflammation and microglial priming in early Alzheimer's Disease

Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and downstream neurodegeneration in preclinical and prodromal AD.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Complement-Mediated Synaptic Protection starts from the claim that modulating C1QA within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Complement-Mediated Synaptic Protection starts from the claim that modulating C1QA within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Complement-Mediated Synaptic Protection ### Mechanistic Hypothesis Overview The "Complement-Mediated Synaptic Protection" hypothesis proposes that excessive activation of the classical complement cascade — specifically the C1q-C3-C3aR and C4b pathways — drives synaptic loss in Alzheimer's disease by tagging synapses for microglial phagocytosis, and that complement pathway inhibition can preserve synapses and protect cognition. The central mechanistic claim is that Aβ oligomers and hyperphosphorylated tau activate the complement cascade in a neuronal activity-dependent manner, leading to localized C1q deposition on vulnerable synapses, C3 fragment opsonization, and microglial phagocytosis through CR3 receptors. ### Biological Rationale and Disease Context The complement system is a critical bridge between innate immunity and synaptic pruning during development. During normal brain development, microglia eliminate excess synapses through a complement-dependent mechanism: astrocytes secrete C1q, which localizes to synapses; neuronal activity and microglia-derived signals trigger C3 cleavage; C3b/iC3b opsonization marks synapses for phagocytosis by microglia expressing CR3 (ITGAM/CD11b-CD18). This developmental pruning is essential for neural circuit formation. In AD, this pathway appears to be inappropriately reactivated, driving synaptic loss that correlates more strongly with cognitive impairment than amyloid or tau burden. Evidence for complement involvement in AD includes: (1) C1q, C3, and C4 are upregulated in AD human brain tissue at transcript and protein levels; (2) C1q localizes to synapses in AD brain, particularly in regions of Aβ deposition; (3) Mouse models lacking C1q, C3, or CR3 (ITGAM) show reduced synaptic loss in response to Aβ challenge; (4) C1q activation by Aβ oligomers triggers a pro-inflammatory response in microglia through C1qR-mediated NF-κB activation, linking complement to neuroinflammation; (5) C4B copy number variation is associated with AD risk in genome-wide studies. ### Detailed Mechanistic Model Stage 1, complement activation trigger: Aβ oligomers and/or phosphorylated tau activate the classical complement pathway by binding C1q directly (Aβ oligomers) or through IgG antibodies (crossing the compromised blood-brain barrier) or through astrocyte-derived C1q. Stage 2, C3 cleavage and opsonization: activated C1s cleaves C4 and then C3; C3b and iC3b fragments covalently tag nearby synapses. Stage 3, microglial recognition: microglia expressing CR3 (CD11b/CD18 heterodimer) recognize C3b/iC3b on synapses and initiate phagocytosis. Stage 4, synaptic engulfment and loss: the affected dendritic spines are physically removed by microglia within hours of opsonization, without an intact C1q-C3 checkpoint, this process is irreversible once initiated. Stage 5, therapeutic intervention point: anti-C1q antibodies, C3 inhibitors (compstatin analogs), or CR3 antagonists can block this cascade at different points, preserving synaptic density and protecting circuit function. ### Evidence For the Hypothesis Supporting evidence: (1) C1q-deficient mice show reduced synaptic loss following Aβ injection or in 5xFAD crossed with C1qa knockout mice; (2) C3-deficient or CR3-deficient mice are protected from synaptic loss and cognitive decline in multiple AD models; (3) Anti-C1q therapeutic antibodies (ANX-005, developed for lupus) have been tested in human trials with acceptable safety; (4) C3-targeted therapeutics (pegcetacoplan,ravulizumab) are approved for other indications and cross the BBB in preclinical models; (5) Human genetics: C4 copy number and C4A expression levels are associated with AD risk, with higher C4A increasing risk. ### Evidence Against and Key Uncertainties Counterevidence and limitations: (1) Complement inhibition may impair normal synaptic remodeling and plasticity, which depend on baseline complement-mediated pruning; chronic complement blockade could cause synaptic overgrowth or maladaptive circuit formation; (2) Complement has complex and sometimes protective roles in AD — C1q can protect neurons from Aβ toxicity in some contexts through neuroprotective signaling; (3) Timing of intervention is critical — complement inhibition may be most effective in early disease stages before synapses are already lost; (4) Systemically administered complement inhibitors have limited BBB penetration; CNS-targeted delivery requires sophisticated formulation; (5) The relationship between tau pathology and complement activation is not fully resolved — tau may activate complement independently of Aβ. ### Translational and Clinical Development Path The most tractable near-term approach is repositioning existing anti-C1q antibodies (ANX-005) or C3 inhibitors (pegcetacoplan) for AD, using intrathecal or intraventricular delivery to achieve adequate CNS concentrations. Biomarker strategy: CSF C3a and C4a as pharmacodynamic markers of complement inhibition, CSF neurofilament light (NfL) as a marker of neuronal integrity. Clinical trial design: early-stage AD patients (CDR 0.5-1) with biomarker-confirmed amyloid pathology, randomized to complement inhibitor versus placebo, with co-primary endpoints of cognitive change (ADAS-Cog13, CDR-SB) and synaptic integrity (CSF NfL trajectory). ### Clinical Relevance and Patient Impact Synaptic loss is the strongest neuroanatomical correlate of cognitive impairment in AD — more predictive than amyloid or tau burden. A therapy that directly preserves synapses would address the most proximate driver of cognitive decline. Complement inhibitors have been safely used in other diseases, potentially enabling faster regulatory pathways than entirely novel drug classes. ### Conclusion Complement-mediated synaptic protection is a mechanistically compelling and genetically validated hypothesis that targets the most proximal driver of cognitive decline in AD. The availability of clinical-stage complement inhibitors and robust human genetics support makes this a high-priority therapeutic strategy." Framed more explicitly, the hypothesis centers C1QA within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.40, novelty 0.60, feasibility 0.50, impact 0.70, and mechanistic plausibility 0.60. ## Molecular and Cellular Rationale The nominated target genes are `C1QA` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors. Identifier 36600274. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease. Identifier 36747024. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Identifier 27114033. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta. Identifier 39129007. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline. Identifier 40515808. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Sustained inhibitory dysfunction in complement component C1qa-deficient mice underlies epilepsy and comorbidities. Identifier 41544964. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Early complement genes are associated with visual system degeneration in multiple sclerosis. Identifier 31289819. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. Identifier 35990663. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into disease pathophysiology. Identifier 40972649. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6188`, debate count `3`, citations `5`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement-Mediated Synaptic Protection". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating C1QA or the surrounding pathway space around Classical complement cascade can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.40, novelty 0.60, feasibility 0.50, impact 0.70, and mechanistic plausibility 0.60.

Molecular and Cellular Rationale

The nominated target genes are `C1QA` and the pathway label is `Classical complement cascade`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA or Classical complement cascade is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors. Identifier 36600274. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease. Identifier 36747024. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Identifier 27114033. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta. Identifier 39129007. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline. Identifier 40515808. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Sustained inhibitory dysfunction in complement component C1qa-deficient mice underlies epilepsy and comorbidities. Identifier 41544964. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Early complement genes are associated with visual system degeneration in multiple sclerosis. Identifier 31289819. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. Identifier 35990663. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into disease pathophysiology. Identifier 40972649. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6188`, debate count `3`, citations `5`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Complement-Mediated Synaptic Protection".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting C1QA within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Amyloid beta oligomers"]
    B["Hyperphosphorylated tau"]
    C["C1QA gene expression"]
    D["C1q protein deposition"]
    E["Classical complement activation"]
    F["C3 convertase formation"]
    G["C3b opsonization"]
    H["C4b pathway activation"]
    I["Microglial CR3 receptors"]
    J["Synaptic phagocytosis"]
    K["Synaptic loss"]
    L["Cognitive decline"]
    M["Complement inhibitors"]
    N["C3aR antagonists"]
    O["Neuroprotective therapy"]

    A -->|"activates"| E
    B -->|"triggers"| E
    C -->|"upregulates"| D
    D -->|"initiates"| E
    E -->|"forms"| F
    F -->|"generates"| G
    E -->|"activates"| H
    G -->|"targets synapses"| I
    H -->|"enhances"| I
    I -->|"promotes"| J
    J -->|"causes"| K
    K -->|"leads to"| L
    M -->|"blocks"| E
    N -->|"inhibits"| I
    O -->|"prevents"| K

    classDef mechanism fill:#4fc3f7
    classDef pathology fill:#ef5350
    classDef therapy fill:#81c784
    classDef outcome fill:#ffd54f
    classDef genetics fill:#ce93d8

    class A,B,D,E,F,G,H mechanism
    class I,J,K,L pathology
    class M,N,O therapy
    class C genetics

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for C1QA from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

12 citations 12 with PMID Validation: 85% 9 supporting / 3 opposing

✓ For (9)

No supporting evidence

No opposing evidence

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 0GENE 3EPID 1

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Prolonged anesthesia induces neuroinflammation and…	Supporting	MECH	BMC Med	-	2023	-	PMID:36600274	-
Perivascular cells induce microglial phagocytic st…	Supporting	MECH	Nat Neurosci	-	2023	-	PMID:36747024	-
Progranulin Deficiency Promotes Circuit-Specific S…	Supporting	GENE	Cell	-	2016	-	PMID:27114033	-
The dopamine analogue CA140 alleviates AD patholog…	Supporting	MECH	J Neuroinflamma…	-	2024	-	PMID:39129007	-
Synaptic pruning genes networks in Alzheimer'…	Supporting	GENE	Geroscience	-	2026	0.33	PMID:40515808	-
Sustained inhibitory dysfunction in complement com…	Supporting	MECH	Prog Neurobiol	-	2026	0.33	PMID:41544964	-
Phosphoproteomics uncovers a neuroimmune perspecti…	Supporting	MECH	Front Immunol	-	2026	0.33	PMID:41853292	-
Robust characterization and interpretation of rare…	Supporting	EPID	Nat Commun	-	2026	0.33	PMID:41547856	-
Structural signature of plasma proteins classifies…	Supporting	MECH	Nat Aging	-	2026	0.33	PMID:41760935	-
Early complement genes are associated with visual …	Opposing	GENE	Brain	-	2019	-	PMID:31289819	-
Single-cell RNA sequencing reveals distinct immuno…	Opposing	MECH	Front Immunol	-	2022	-	PMID:35990663	-
Proteomic discoveries in hypermobile Ehlers-Danlos…	Opposing	MECH	Immunohorizons	-	2025	-	PMID:40972649	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 9

Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involve…▼

Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors.

BMC Med · 2023 · PMID:36600274

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alz…▼

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.

Nat Neurosci · 2023 · PMID:36747024

Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.

Cell · 2016 · PMID:27114033

The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functio…▼

The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.

J Neuroinflammation · 2024 · PMID:39129007

Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline…▼

Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline.

Geroscience · 2026 · PMID:40515808 · Q:0.33

Sustained inhibitory dysfunction in complement component C1qa-deficient mice underlies epilepsy and comorbidit…▼

Sustained inhibitory dysfunction in complement component C1qa-deficient mice underlies epilepsy and comorbidities.

Prog Neurobiol · 2026 · PMID:41544964 · Q:0.33

Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: sexually dimorphic regulatory ne…▼

Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: sexually dimorphic regulatory networks linking calcium channels to the complement cascade.

Front Immunol · 2026 · PMID:41853292 · Q:0.33

Robust characterization and interpretation of rare pathogenic cell populations from spatial omics using GARDEN…▼

Robust characterization and interpretation of rare pathogenic cell populations from spatial omics using GARDEN.

Nat Commun · 2026 · PMID:41547856 · Q:0.33

Structural signature of plasma proteins classifies the status of Alzheimer's disease.

Nat Aging · 2026 · PMID:41760935 · Q:0.33

✗ Opposing Evidence 3

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Brain · 2019 · PMID:31289819

Single-cell RNA sequencing reveals distinct immunology profiles in human keloid.

Front Immunol · 2022 · PMID:35990663

Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into disease pathophysiology.

Immunohorizons · 2025 · PMID:40972649

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 3 rounds | 2026-04-04 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Neuroinflammation and Microglial Priming in Early Alzheimer's Disease: A Theorist's Perspective

The Central Hypothesis: Context-Dependent Priming as a Convergent Mechanism

I argue that microglial priming represents a critical missing link between early-life immune challenges and late-onset Alzheimer's disease pathology, yet our current framework fundamentally underestimates the temporal dynamics and context-dependence of this process. The prevailing model treats microglia as either beneficial (disease-associated microglia/DAM) or harmful (pro-inflammatory), when evidence suggests a

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

The Skeptic's Case: Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Priming Hypothesis: Compelling but Incomplete

The hypothesis that microglial priming drives early Alzheimer's disease pathophysiology presents an intellectually elegant narrative: repeated peripheral infections or inflammatory insults "prime" microglia, rendering them hyperresponsive to subsequent challenges, thereby accelerating neurodegeneration. This framework successfully integrates several observations—the documented presence of activated microglia in AD brains, the epidemiological associa

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Round: Gap Analysis — Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Established Evidence Base

The neuroinflammatory hypothesis of Alzheimer's disease (AD) has matured considerably from a peripheral observation to a genetically validated mechanistic framework. The strongest evidence comes from AD genetics: TREM2 (triggering receptor expressed on myeloid cells 2) and its obligate signaling partner TYROBP (DAP12) harbor loss-of-function variants that increase AD risk approximately 2-3 fold — a magnitude comparable to APOE ε4 (Ope

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0118

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.445	▲ 2.7%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.433	▲ 5.5%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.410	▼ 1.4%		2026-04-10 15:58
⚖	Recalibrated	$0.416	▼ 4.9%		2026-04-10 15:53
📄	New Evidence	$0.437	▼ 8.8%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.479	▲ 17.1%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.409	▲ 0.7%		2026-04-08 18:39
💬	Debate Round	$0.406	▼ 24.2%	market_dynamics	2026-04-05 02:02
📄	New Evidence	$0.536	▲ 62.3%	market_dynamics	2026-04-05 01:03
📊	Score Update	$0.330	▼ 28.3%	market_dynamics	2026-04-05 00:19
📊	Score Update	$0.461	▲ 6.2%	market_dynamics	2026-04-04 22:07
💬	Debate Round	$0.433	▼ 30.1%	market_dynamics	2026-04-04 20:45
💬	Debate Round	$0.620	▲ 74.4%	market_dynamics	2026-04-04 20:29
📄	New Evidence	$0.356	▼ 12.9%	market_dynamics	2026-04-04 19:10
⚖	Recalibrated	$0.408	▼ 0.8%		2026-04-04 16:38

Clinical Trials (1) Relevance: 58%

0
Active

0
Completed

0
Total Enrolled

Untitled Trial Unknown

Unknown ·

📚 Cited Papers (17)

Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.

Cell (2016) · PMID:27114033

No extracted figures yet

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Brain (2019) · PMID:31289819

No extracted figures yet

Single-cell RNA sequencing reveals distinct immunology profiles in human keloid.

Frontiers in immunology (2022) · PMID:35990663

No extracted figures yet

Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors.

BMC Med (2023) · PMID:36600274

No extracted figures yet

Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.

Nat Neurosci (2023) · PMID:36747024

No extracted figures yet

The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.

Journal of neuroinflammation (2024) · PMID:39129007

No extracted figures yet

Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline.

GeroScience (2026) · PMID:40515808

No extracted figures yet

Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into disease pathophysiology.

ImmunoHorizons (2025) · PMID:40972649

No extracted figures yet

Sustained inhibitory dysfunction in complement component C1qa-deficient mice underlies epilepsy and comorbidities.

Progress in neurobiology (2026) · PMID:41544964

No extracted figures yet

Robust characterization and interpretation of rare pathogenic cell populations from spatial omics using GARDEN.

Nat Commun (2026) · PMID:41547856

No extracted figures yet

Structural signature of plasma proteins classifies the status of Alzheimer's disease.

Nat Aging (2026) · PMID:41760935

No extracted figures yet

Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: sexually dimorphic regulatory networks linking calcium channels to the complement cascade.

Frontiers in immunology (2026) · PMID:41853292

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Neuroinflammation and microglial priming in early Alzheimer's Disease — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-04-gap-20260404-microglial-priming-early-ad. Investigate mechanistic links between early microglial priming states, neuroinflammatory signaling, and …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.47

21.0th percentile (776 hypotheses)

Tokens Used

15,155

KG Edges Generated

713

Citations Produced

Cost Ratios

Cost per KG Edge

141.64 tokens

Lower is better (baseline: 2000)

Cost per Citation

1262.92 tokens

Lower is better (baseline: 1000)

Cost per Score Point

30069.44 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.047

10% weight of efficiency score

Adjusted Composite

0.626

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.423	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for C1QA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for C1QA →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (88)

2 AD_pathology AD_related_microglial_activation AD_susceptibility APOE APOE4 ARNTL Alzheimer's disease Alzheimer_disease C1Q C1QA C1QA, C3, CX3CR1, CX3CL1 C3 CLOCK CLOCK, ARNTL CX3CR1 DNMT1 DNMT3A DNMT3A, HDAC1/2 GPR109A

Dependency Graph (3 upstream, 0 downstream)

Depends On

Complement C1q Mimetic Decoy Therapyrefines (0.5)Complement C1q Subtype Switchingrefines (0.5)Complement-Mediated Synaptic Pruning Dysregulationrefines (0.5)

Linked Experiments (9)

Related Hypotheses

Complement C1q Mimetic Decoy Therapy

Score: 0.695 | neurodegeneration

Complement C1QA Spatial Gradient in Cortical Layers

Score: 0.678 | Alzheimer's Disease

Complement C1q Subtype Switching

Score: 0.665 | neurodegeneration

Complement-Mediated Synaptic Pruning Dysregulation

Score: 0.612 | neurodegeneration

microglial priming across neurodegenerative diseases should remain under review until replicated

Score: 0.577 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

4.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF C1QA is genetically knocked out in APP/PS1 transgenic mice (a model of Alzheimer's disease) THEN synaptic density (measured by PSD-95 and synaptophysin western blot or immunohistochemistry) will be significantly preserved compared to littermate controls, AND microglial engulfment of synaptic material (measured by confocal microscopy of CD68+ Iba1+ microglia with synaptic markers) will be reduced by at least 50% within 6 months of disease progression using an APP/PS1;C1qa-/- double transgenic mouse model.

pending conf: 0.75

Expected outcome: Synaptic marker density will be 40-60% higher in C1QA knockout AD mice compared to AD mice with intact C1QA. Microglial phagocytosis of synapses will show a statistically significant reduction (p<0.05).

Falsified by: If C1QA knockout in APP/PS1 mice produces no significant difference in synaptic density (≤10% change) or microglial synaptic engulfment compared to C1QA wild-type APP/PS1 mice, the complement-mediated synaptic loss hypothesis would be falsified, suggesting C1QA is not a critical driver of amyloid-induced synaptic elimination.

Method: Cross APP/PS1 AD transgenic mice with C1qa-/- mice to generate experimental and control genotypes. Use stereology-based synaptic quantification in hippocampus (CA1 stratum radiatum), Western blot quantification of pre- and post-synaptic proteins, and two-photon imaging of microglial-synapse interactions in living mice. Cognitive testing (Morris water maze, Y-maze) at 6 and 12 months.

IF human iPSC-derived neurons expressing familial AD mutations (APP Swe, PSEN1) are treated with a selective C1QA-blocking antibody or C1QA siRNA prior to exposure to Aβ42 oligomers (500 nM, 24 hours), THEN the number of dendritic spines (measured by live-cell imaging of GFP-labeled neurons) will remain stable (≤15% loss) and complement C3 deposition on neurons (measured by flow cytometry) will be reduced by >70% compared to Aβ42-treated neurons without C1QA inhibition within 48 hours of treatment using human iPSC-derived cortical neuron-microglia co-cultures.

pending conf: 0.68

Expected outcome: C1QA inhibition will prevent Aβ42-induced spine loss and reduce C3 opsonization by 70-90%. Microglia in co-culture will show reduced phagocytic activity toward neurons (measured by pHrodo-synaptophysin engulfment assay).

Falsified by: If C1QA blockade does NOT prevent Aβ42-induced dendritic spine loss (spine loss remains >40% similar to untreated controls) OR C3 deposition is not reduced, this would falsify the hypothesis that C1QA mediates Aβ-triggered complement-dependent synaptic pruning. Additionally, if pharmacological C1QA inhibition produces identical results to vehicle control, the pathway is not operative in this system.

Method: Differentiate human iPSCs into cortical neurons and co-culture with iPSC-derived microglia. Transfect neurons with GFP for spine visualization. Pre-treat with anti-C1QA antibody (Clone 278779, R&D Systems) or C1QA siRNA 48 hours before Aβ42 oligomer exposure. Quantify spines using live-cell confocal imaging at 0, 24, and 48 hours. Measure C1Q and C3 deposition by immunocytochemistry and flow cytometry. Include isotype antibody controls and C3CR1 antagonist (SB290157) as positive control for comp

Knowledge Subgraph (120 edges)

activates (1)

TLR4→microglial_activation

associated with (9)

C1QA, C3, CX3CR1, CX3CL1→Alzheimer's diseaseCLOCK, ARNTL→Alzheimer's diseaseDNMT3A, HDAC1/2→Alzheimer's diseaseGPR43, GPR109A→Alzheimer's diseaseHIF1A, NFKB1→Alzheimer's disease

▸ Show 4 more

IGFBPL1→neurodegenerationIL1B, TNFA, NLRP3→Alzheimer's diseaseMultiple→neurodegenerationTNF/IL6→neurodegeneration

associated with microglial priming (12)

DNMT3A→Alzheimer's diseaseHDAC1→Alzheimer's diseaseHDAC2→Alzheimer's diseaseCX3CR1→Alzheimer's diseaseIGFBPL1→Alzheimer's disease

▸ Show 7 more

TNFA→Alzheimer's diseaseGPR43→Alzheimer's diseaseGPR109A→Alzheimer's diseaseHIF1A→Alzheimer's diseaseNFKB1→Alzheimer's diseaseCLOCK→Alzheimer's diseaseARNTL→Alzheimer's disease

▸ Show 4 more

perinatal_asphyxia→microglial_primingTNF→AD_related_microglial_activationneuroinflammation→synaptic_dysfunctiongut_dysbiosis→microglial_activation

co associated with (34)

APOE→TNF/IL6APOE→MultipleC1QA, C3, CX3CR1, CX3CL1→HIF1A, NFKB1C1QA, C3, CX3CR1, CX3CL1→CLOCK, ARNTLC1QA, C3, CX3CR1, CX3CL1→IL1B, TNFA, NLRP3

▸ Show 29 more

C1QA, C3, CX3CR1, CX3CL1→IGFBPL1C1QA, C3, CX3CR1, CX3CL1→DNMT3A, HDAC1/2CLOCK, ARNTL→IL1B, TNFA, NLRP3CLOCK, ARNTL→IGFBPL1CLOCK, ARNTL→DNMT3A, HDAC1/2C1QA, C3, CX3CR1, CX3CL1→GPR43, GPR109AGPR43, GPR109A→HIF1A, NFKB1CLOCK, ARNTL→GPR43, GPR109AGPR43, GPR109A→IL1B, TNFA, NLRP3GPR43, GPR109A→IGFBPL1DNMT3A, HDAC1/2→GPR43, GPR109ACLOCK, ARNTL→HIF1A, NFKB1HIF1A, NFKB1→IL1B, TNFA, NLRP3HIF1A, NFKB1→IGFBPL1DNMT3A, HDAC1/2→HIF1A, NFKB1APOE→IGFBPL1IGFBPL1→TNF/IL6IGFBPL1→MultipleIGFBPL1→TREM2C1QA→IGFBPL1DNMT3A, HDAC1/2→IGFBPL1IGFBPL1→IL1B, TNFA, NLRP3DNMT3A, HDAC1/2→IL1B, TNFA, NLRP3Multiple→TREM2C1QA→MultipleMultiple→TNF/IL6TNF/IL6→TREM2C1QA→TNF/IL6Multiple→Multiple

co discussed (2)

C3→CX3CR1APOE4→LRRK2

erases (1)

epigenetic_reprogramming→inflammatory_memory

implicated in (14)

h-6f1e8d32→neurodegenerationh-6880f29b→neurodegenerationh-f19b8ac8→neurodegenerationh-69bde12f→neurodegenerationh-6f21f62a→neurodegeneration

▸ Show 9 more

h-ea3274ff→neurodegenerationh-8f9633d9→neurodegenerationh-e5f1182b→Alzheimer's diseaseh-494861d2→Alzheimer's diseaseh-d4ff5555→Alzheimer's diseaseh-cc1076c1→Alzheimer's diseaseh-48775971→Alzheimer's diseaseh-646ae8f1→Alzheimer's diseaseh-828b3729→Alzheimer's disease

induces (1)

IL10→microglial_tolerance

inhibits (1)

IGFBPL1→neuroinflammation

maintains (1)

P2RY12→homeostatic_microglia

mediates (1)

C1QA→synaptic_pruning

modulates (6)

microbiota→microglia_activationDNMT3A→microglial_activation_thresholdsIL10→microglial_memoryepigenetic_reprogramming→aged_microgliaTLR4→gut_brain_signaling

▸ Show 1 more

DNMT3A→microglial_activation_threshold

prevents (4)

IGFBPL1→tau_pathologymicroglial_homeostasis→tau_spreadepigenetic_reprogramming→microglial_dysfunctionIGFBPL1→neuroinflammation

programs (1)

perinatal_inflammation→microglial_priming

promotes (1)

TREM2→disease_associated_microglia

protective against (2)

microglial_surveillance→neuroprotectionmicroglial_homeostasis→AD_pathology

regulates (5)

IGFBPL1→microglial_homeostasisC1Q→synaptic_pruningDNMT1→inflammatory_memoryDNMT1→microglial_epigenetic_landscapeDNMT1→microglial_chromatin_landscape

risk factor for (6)

TNF→vascular_cognitive_impairmentperinatal_asphyxia→AD_susceptibilitymicroglial_priming→Alzheimer_diseaseage_related_microglial_dysfunction→AD_pathologymicroglial_priming→AD_susceptibility

▸ Show 1 more

microglial_priming→AD_pathology

spreads via (1)

tau_pathology→neuroinflammation

targets (6)

h-6880f29b→IGFBPL1h-6f21f62a→Multipleh-8f9633d9→Multipleh-e5f1182b→2h-d4ff5555→IGFBPL1

▸ Show 1 more

h-48775971→GPR43

Mechanism Pathway for C1QA

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    C1QA["C1QA"] -->|mediates| synaptic_pruning["synaptic_pruning"]
    C1QA__C3__CX3CR1__CX3CL1["C1QA, C3, CX3CR1, CX3CL1"] -->|associated with| Alzheimer_s_disease["Alzheimer's disease"]
    C1QA__C3__CX3CR1__CX3CL1_1["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| HIF1A__NFKB1["HIF1A, NFKB1"]
    C1QA__C3__CX3CR1__CX3CL1_2["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| CLOCK__ARNTL["CLOCK, ARNTL"]
    C1QA__C3__CX3CR1__CX3CL1_3["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| IL1B__TNFA__NLRP3["IL1B, TNFA, NLRP3"]
    C1QA__C3__CX3CR1__CX3CL1_4["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| IGFBPL1["IGFBPL1"]
    C1QA__C3__CX3CR1__CX3CL1_5["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| DNMT3A__HDAC1_2["DNMT3A, HDAC1/2"]
    C1QA__C3__CX3CR1__CX3CL1_6["C1QA, C3, CX3CR1, CX3CL1"] -->|co associated with| GPR43__GPR109A["GPR43, GPR109A"]
    C1QA_7["C1QA"] -->|co associated with| IGFBPL1_8["IGFBPL1"]
    C1QA_9["C1QA"] -->|co associated with| Multiple["Multiple"]
    C1QA_10["C1QA"] -->|co associated with| TNF_IL6["TNF/IL6"]
    style C1QA fill:#ce93d8,stroke:#333,color:#000
    style synaptic_pruning fill:#4fc3f7,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1 fill:#ce93d8,stroke:#333,color:#000
    style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_1 fill:#ce93d8,stroke:#333,color:#000
    style HIF1A__NFKB1 fill:#ce93d8,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_2 fill:#ce93d8,stroke:#333,color:#000
    style CLOCK__ARNTL fill:#ce93d8,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_3 fill:#ce93d8,stroke:#333,color:#000
    style IL1B__TNFA__NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_4 fill:#ce93d8,stroke:#333,color:#000
    style IGFBPL1 fill:#ce93d8,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_5 fill:#ce93d8,stroke:#333,color:#000
    style DNMT3A__HDAC1_2 fill:#ce93d8,stroke:#333,color:#000
    style C1QA__C3__CX3CR1__CX3CL1_6 fill:#ce93d8,stroke:#333,color:#000
    style GPR43__GPR109A fill:#ce93d8,stroke:#333,color:#000
    style C1QA_7 fill:#ce93d8,stroke:#333,color:#000
    style IGFBPL1_8 fill:#ce93d8,stroke:#333,color:#000
    style C1QA_9 fill:#ce93d8,stroke:#333,color:#000
    style Multiple fill:#ce93d8,stroke:#333,color:#000
    style C1QA_10 fill:#ce93d8,stroke:#333,color:#000
    style TNF_IL6 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 C1QA — PDB 1PK6 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Neuroinflammation and microglial priming in early Alzheimer's Disease

neurodegeneration | 2026-04-04 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Microbiota-Microglia Axis Modulation

Score: 0.65 · Multiple

Epigenetic Reprogramming of Microglial Memory

Score: 0.65 · DNMT3A, HDAC1/2

Cardiovascular-Neuroinflammatory Dual Targeting

Score: 0.63 · TNF/IL6

Perinatal Immune Challenge Prevention

Score: 0.62 · Multiple

Synaptic Pruning Precision Therapy

Score: 0.61 · C1QA, C3, CX3CR1, CX3CL1

→ View all analysis hypotheses

Complement-Mediated Synaptic Protection

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 9

✗ Opposing Evidence 3

Neuroinflammation and Microglial Priming in Early Alzheimer's Disease: A Theorist's Perspective

The Central Hypothesis: Context-Dependent Priming as a Convergent Mechanism

The Skeptic's Case: Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Priming Hypothesis: Compelling but Incomplete

Domain Expert Round: Gap Analysis — Neuroinflammation and Microglial Priming in Early Alzheimer's Disease

The Established Evidence Base

Price History

Clinical Trials (1) Relevance: 58%

📚 Cited Papers (17)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (7)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (88)

Dependency Graph (3 upstream, 0 downstream)

Linked Experiments (9)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (120 edges)

activates (1)

associated with (9)

associated with microglial priming (12)

biomarker for (1)

causal extracted (1)

causes (9)

co associated with (34)

co discussed (2)

erases (1)

implicated in (14)

induces (1)

inhibits (1)

maintains (1)

mediates (1)

modulates (6)

prevents (4)

programs (1)

promotes (1)

protective against (2)

regulates (5)

risk factor for (6)

spreads via (1)

targets (6)

Mechanism Pathway for C1QA

3D Protein Structure

Source Analysis

Neuroinflammation and microglial priming in early Alzheimer's Disease

Community Feedback

Same Analysis (5)